Winton Group Increases Stake in TG Therapeutics Amid Biotech Commercial Scaling
Winton Group Ltd has acquired 113,951 shares of TG Therapeutics, signaling institutional confidence in the biotech firm's commercial execution. The move follows recent financial disclosures and suggests a data-driven endorsement of the company's growth trajectory in the multiple sclerosis market.